MEI Pharma Q2 2024 GAAP EPS $(1.66) Misses $(1.32) Estimate
Portfolio Pulse from Benzinga Newsdesk
MEI Pharma (NASDAQ:MEIP) reported a Q2 2024 GAAP EPS loss of $(1.66), missing the analyst consensus estimate of $(1.32) by 25.76%.
February 13, 2024 | 10:08 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
MEI Pharma reported a larger than expected loss for Q2 2024, with a GAAP EPS of $(1.66) compared to the estimated $(1.32).
Missing the earnings estimate by 25.76% is significant and typically results in negative investor sentiment in the short term. This larger than expected loss could lead to a decrease in stock price as investors adjust their expectations.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100